Variables | β2-agonists group (n = 67) | Control group (n = 67) | P-value |
---|---|---|---|
Age, years | 71.4 ± 7.4 | 70.5 ± 8.5 | 0.503 |
Gender (male) | 53 (79%) | 52 (78%) | 0.834 |
Comorbidities (HT/DL/DM/IHD) | 19/8/9/3 | 18/9/10/3 | NS |
Smoking history | 61 (91%) | 59 (88%) | 0.572 |
Surgical procedure (VATS) | 22 (33%) | 29 (43%) | 0.213 |
Lung cancer staging (I/II/III/IV) | 46/7/12/2 | 42/6/16/3 | NS |
VC, % predicted | 95.7 ± 14.2 | 97.6 ± 16.9 | 0.475 |
FEV1, % predicted | 70.6 ± 14.9 | 75.0 ± 17.0 | 0.108 |
FEV1/FVC, % | 58.2 ± 8.6 | 60.2 ± 7.0 | 0.145 |